- Company
- Ilyang's Supect, good effect on leukemia cells reduction
- by Jung, Hye-Jin Feb 10, 2020 06:30am
- Ilyang announced that its phase III clinical trial of 'Supect', a leukemia treatment drug developed by the company, outperformed than Glivec. Ilyang Pharmaceutical (President Kim Dong-yeon) announced on the 6th that the clinical results were published in British journal of Hematology. In this trial, 241 patients with chronic myelogenous
- Policy
- HIRA to tighten personal data protection for committees
- by Lee, Hye-Kyung Feb 10, 2020 06:30am
- Drug reimbursement feasibility deliberating Health Insurance Review and Assessment Service (HIRA) plans to tighten operational regulation for its associated committees. The revised regulation would minimize collection of committee member’s private information and generally strengthen protection of personal information. HIRA’s Benefit L
- Policy
- Rucalo newly listed, Meqsel+Rafinlar expands reimbursement
- by Kim, Jung-Ju Feb 10, 2020 06:30am
- Healthcare reimbursement would be granted on Yooyoung Pharmaceutical’s chronic constipation treatment Rocalo tablet (prucalopride succinate) soon at a price of 100 won a unit. Used to treat BRAF V600E mutation-confirmed metastatic melanoma, Novartis Korea’s Meqsel (trametinib dimethyl sulfoxide) plus Rafinlar (dabrafenib mesylate) combin
- Company
- MFDS to clear Forxiga’s heart failure indication soon
- by Eo, Yun-Ho Feb 10, 2020 12:17am
- Anti-diabetic treatment Forxiga is ready to be reintroduced as a heart failure drug in Korean market as well. According to pharmaceutical industry on Feb. 7, AstraZeneca’s sodium-glucose cotransporter 2 (SGLT-2) inhibitor Forxiga (dapagliflozin) would be soon indicated for reducing the risk of hospitalization by heart failure in patients
- Policy
- NIH, urgently promotes 2019n-CoV vaccine research
- by Kim, Jung-Ju Feb 7, 2020 06:32am
- Health authorities urgently push forward research to develop 2019n-CoV treatments and vaccines. After the MERS outbreak, it will strengthen its research capabilities and begin research on viral pathogenicity within this month. The National Institutes of Health (Director Hyun-Young Park), in the Centers for Disease Control and Prevention
- Policy
- Feb shortage prevention drug list: 641 items with Vivaquine
- by Lee, Hye-Kyung Feb 7, 2020 06:32am
- Myung In Pharmaceutical’s Vivaquine tablet (primaquine phosphate) has been designated as a shortage prevention drug as compensation for high production cost. The maximum price is set at 309 won. Health Insurance Review and Assessment Service (HIRA) recently disclosed new list of shortage prevention drug as of February 2020. ‘Shorta
- Policy
- DREC to deliberate drug reevaluation as originally planned
- by Kim, Jung-Ju Feb 7, 2020 06:32am
- Although committee meetings and events by Korean government and associated agencies have been either canceled or postponed due to the novel coronavirus, Drug Reimbursement Evaluation Committee (DREC) plans to push on with its original schedules as it plays the role of the first threshold to drug reimbursement listing and criteria negotiation
- Company
- Opdivo retries expanding reimbursement without NSCLC
- by Eo, Yun-Ho Feb 6, 2020 06:31am
- Seemingly have given up on expanding reimbursement, Opdivo has turned around and started taking actions again. Nevertheless, its health coverage application excluded indication for lung cancer. According to industry sources, Ono Pharmaceutical and BMS have recently applied for expanding reimbursement on PD-1 inhibitor-based immunotherapy
- Company
- Pelubi’s indication expansion, seeking for breakthrough
- by Kim, Jin-Gu Feb 6, 2020 06:30am
- Daewon Pharm challenges the expansion of Pelubi's patented indication. Pelubi's indication for osteoarthritis is extended to dysmenorrhea. Recently, Pelubi CR’s phase III trial plan by Daewon was approved from the Ministry of Food and Drug Safety. This is a phase III clinical trial in Korea to evaluate the efficacy and safety of DW9801
- Policy
- 2019n-CoV was successfully isolated from infected patients
- by Kim, Jung-Ju Feb 6, 2020 06:30am
- Health authorities have successfully isolated the new coronavirus (wuhan pneumonia) from patients with infectious diseases, It is very good news for developing vaccines and treatments The KCDC(Director, Eun-kyung Chung) announced on the 5th that 2019n-CoV was isolated and will share with the scientific community for the development of vaccine
